MARKSANS vs WINDLAS: Stock Comparison

Marksans Pharma Limited vs Windlas Biotech Ltd

Live data: 22 July 2026, 2:59 PM IST • Source: NSE and company filings

Marksans Pharma Limited is the larger company by market capitalisation. Marksans Pharma Limited shows a higher ROE, faster revenue growth and a higher ROCE, while Windlas Biotech Ltd shows a lower P/E, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Marksans Pharma Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MARKSANS is more favourable on 8 of 13 scored metrics and WINDLAS on 5These counts are context-free and are not an overall rating.

Marksans Pharma Limited

Key Differences

Market Cap

MARKSANS is the larger company

₹10,928 Cr vs ₹1,804 Cr

P/E Ratio

WINDLAS has a lower P/E

28x vs 28.31x

P/B Ratio

WINDLAS has a lower P/B

3.2x vs 3.91x

EPS

WINDLAS has higher earnings per share

₹31.5 vs ₹9.71

Dividend Yield

WINDLAS has a higher dividend yield

0.72% vs 0.29%

Revenue Growth (TTM YoY)

MARKSANS has faster revenue growth

20.8% vs 17.7%

EPS Growth (TTM YoY)

MARKSANS has faster EPS growth

63.5% vs -2.6%

Qtr Sales Growth

MARKSANS has stronger quarterly sales growth

20.8% vs 17.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

Metric	MARKSANS	WINDLAS
Sector	Healthcare	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals

Price

Metric	MARKSANS	WINDLAS
Live Price	₹241.1	₹870.6
Day Change	-7.38%	-1.12%
Volume	37.45 L	33,210
52-Week High	₹281.6	₹1,097.9
52-Week Low	₹155	₹697.4
Distance from 52W High	-14.38%	-20.7%

Valuation

Metric	MARKSANS	WINDLAS
Market Cap	₹10,928 Cr	₹1,804 Cr
P/E Ratio	28.31x	28x
P/B Ratio	3.91x	3.2x
EPS	₹9.71	₹31.5
Book Value	₹66.74	₹275
Dividend Yield	0.29%	0.72%

Growth

Metric	MARKSANS	WINDLAS
Revenue Growth (TTM YoY)	20.8%	17.7%
EPS Growth (TTM YoY)	63.5%	-2.6%
Qtr Sales Growth	20.8%	17.7%
Qtr Profit Growth	63.6%	-1.78%

Profitability & Leverage

Metric	MARKSANS	WINDLAS
ROE	15.2%	12.2%
ROCE	18.8%	15.9%
Net Margin	14.16%	7.35%
Operating Margin	20.4%	11.6%
Debt to Equity	0.11x	0.06x

Shareholding

As of Mar 2026 • change vs previous quarter

Metric	MARKSANS	WINDLAS
Promoter Holding	43.87%	63.31%▲ 1.41 pp
FII Holding	16.76%▲ 8.64 pp	2.04%▲ 1.44 pp
DII Holding	6.57%▲ 0.66 pp	9.84%▼ 1.97 pp
Public Holding	32.79%▼ 9.3 pp	24.8%▼ 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Marksans Pharma Limited and Windlas Biotech Ltd.

Related Comparisons

Infosys vs TCS HDFC Bank vs ICICI Bank Axis Bank vs Kotak Mahindra Bank HCL Technologies vs Wipro Hindustan Unilever vs ITC Maruti Suzuki vs Tata Motors

Browse all stock comparisons →

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.